BIEI Stock Overview
A research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Premier Biomedical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0007 |
| 52 Week High | US$0.0021 |
| 52 Week Low | US$0.0006 |
| Beta | 0 |
| 1 Month Change | -12.50% |
| 3 Month Change | -36.36% |
| 1 Year Change | -38.60% |
| 3 Year Change | -75.86% |
| 5 Year Change | 133.33% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIEI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.7% | -0.1% | -0.5% |
| 1Y | -38.6% | -6.4% | 23.2% |
Return vs Industry: BIEI underperformed the US Biotechs industry which returned -7% over the past year.
Return vs Market: BIEI underperformed the US Market which returned 23% over the past year.
Price Volatility
| BIEI volatility | |
|---|---|
| BIEI Average Weekly Movement | 16.3% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BIEI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BIEI's weekly volatility has decreased from 22% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | n/a | www.premierbiomedical.com |
Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. It offers pain management products comprising pain relief patch of hemp oil extracts; water-based and oil-based roll-on applicators; oil-based pump spray applicators; and ointments through its Website painreliefmeds.com and various distributors. It is also developing hemp oil products, including anti-pain patch, roll-on topical products, sprays, ointments, tincture drop product, a hemp oil capsule, and pet product; sequential-dialysis technique for cancer, Alzheimer’s disease, ALS, blood sepsis, leukemia, and other life-threatening cancers; and Feldetrex drug candidate for the treatment of multiple sclerosis, fibromyalgia, neuropathic pain, and traumatic brain injuries.
Premier Biomedical, Inc. Fundamentals Summary
| BIEI fundamental statistics | |
|---|---|
| Market cap | US$769.22k |
| Earnings (TTM) | -US$374.47k |
| Revenue (TTM) | US$14.28k |
0.0x
P/S Ratio0.0x
P/E RatioIs BIEI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIEI income statement (TTM) | |
|---|---|
| Revenue | US$14.28k |
| Cost of Revenue | US$12.86k |
| Gross Profit | US$1.42k |
| Other Expenses | US$375.89k |
| Earnings | -US$374.47k |
Last Reported Earnings
Dec 31, 2019
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did BIEI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 18:44 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Premier Biomedical, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|